Key information

🔎 Fund Overview

Aspira Women's Health Inc. is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Its products include Ova1, Overa, Ova1Plus and OvaWatch. Ova1 is a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity. Ova1Plus is a reflex offering, which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results. OvaWatch is a lab developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass. The Company’s products are distributed through its own national sales force, through its decentralized testing platform.